1Nakamura K, Okamura H, Wada M, et al. Endotoxin-induced serum factor that stimulates gamma interferon product ion [J].Infect Immun, 1989 ;57 (3) :590-6.
2Okamura H, Nagata K, Komatsu T, et al. A novel costimulatory factor for gamma interferon induct ion found in the livers of mice causes endotoxic shock [J]. Infect Immun, 1995 ;63 ( 5 ) : 3966 -72.
3Ushio S, Namba M, Okura T, et al. Cloning of the DNA for human IFN- gamma inducing factor expression in Eschericha coli and studies on the biologic activities of the protein [J]. Immunol, 1996;156 (11 ) :4274.
4Hung J, McQuillan BM, Chapman CM, et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance[J].Immunology,2005 ;96 ( 2 ) :247 -51.
5Nakamura A,Shikata K, Hiramatsu M,et al. Serum interleukin-18 levels are associated with nephropathy and atheroselerosis in Japanese patients with type 2 diabetes[J].Diabetes Care,2005 ;28(12) :2890-5.
6Rothe H ,Jenkins NA, Copeland NG, et al. Active of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2[J].J Clin Invest, 1997 ;99 (3) :469.
7Nicoletti F, Di Marco R, Papaccio G, et al. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant Ⅱ -18-binding protein : Fc construct [J].Eur J Immunol, 2003 ; 33 ( 8 ) : 2278-86.
8Rothe H, Hausmann A, Casteels K, et al. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis [J].Immunology, 1999 ; 163 (3) : 1230.
9Hanifi-Moghaddam P, Schloot NC, Kappler S, et al. An association of autoantibody status and serum cytokine levels in type 1 diabetes [J].Diabetes, 2003 ; 52 ( 5 ) : 1137 -42.
10Katakami N, Kaneto H, Matsuhisa M, et al. Serum interleukin-18 levels are increased and closely associated with various soluble adhesion molecule levels in type 1 diabetic patients[J]. Diabetes,2007;30 (1) :159- 61.
4McInnes IB, Gracie JA, Leung BP, et al. Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol Today,2000, 21:312-315.
5Tahara H, Oikawa Y, Shimada A, et al. Systemic Administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol, 2003, 171: 5865-5875.
6Esposito K, Nappo F, Giugliano F,et al. Cytokine milieu tends toward inflammation in type 2 diabetes (Letter). Diabetes Care,2003, 26:1647.
7Aso Y, Okumura KI, Takebayashi K, et al. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intima-media wall thickness in patients with type 2diabetes. Diabetes Care,2003, 26:2622-2627.
8Mohr S. Potential new strategies to prevent the development of diabetic retinopathy. Expert Opin Investig Drugs, 2004,13: 189-98.
9Renhai C,Jacob F, Masashi K,et al. Interleukin-18 acts as an angiogenesis and tumor suppressor. The FASEB Journal, 1999 ,13: 2195-2202.
10Qiao H, Sonoda KH, Sassa Y, et al. Abnormal retinal vascular development in IL-18 knockout mice. Lab Invest, 2004, 84: 973-80.
